As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win aliu Mon, 10/03/2022 – 11:52 More: As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win Source: fierce
read moreAmid scrutiny around Europe’s vaccine purchase, Pfizer CEO Albert Bourla pulls out of committee hearing zbecker Mon, 10/03/2022 – 11:23 More: Amid scrutiny around Europe's vaccine purchase, Pfizer CEO Albert Bourla pulls out of committee hearing Source: fierce
read moreBiogen’s last-gasp effort to reinstate Tecfidera patent fails at Supreme Court kdunleavy Mon, 10/03/2022 – 11:19 More: Biogen's last-gasp effort to reinstate Tecfidera patent fails at Supreme Court Source: fierce
read moreKite’s viral vector ambitions take flight as the Gilead subsidiary wins FDA nod for SoCal production plant fkansteiner Mon, 10/03/2022 – 10:58 More: Kite's viral vector ambitions take flight as the Gilead subsidiary wins FDA nod for SoCal production plant
read moreAlnylam’s new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst aliu Mon, 10/03/2022 – 10:22 More: Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst Source: fierce
read moreThe anti-inflammatory treatment is for Duchenne muscular dystrophy More: Santhera submits marketing authorisation application for vamorolone Source: News
read more© 1994 - 2022 B.M. Pharmaceuticals